Risk factors for development of paradoxical response during antituberculosis therapy in HIV-negative patients

Eur J Clin Microbiol Infect Dis. 2003 Oct;22(10):597-602. doi: 10.1007/s10096-003-0998-z. Epub 2003 Sep 24.

Abstract

The risk factors for development of paradoxical response were studied in a cohort of 104 patients with culture-documented Mycobacterium tuberculosis infection. Paradoxical deterioration occurred in 16 (15.4%) patients (case group) during antituberculosis therapy, involving lungs and pleura (n=4), spine and paraspinal tissue (n=5), intracranium (n=3), peritoneum (n=2), bone and joint (n=1), and lymph node (n=1). The median time from commencement of treatment to paradoxical deterioration was 56 days (range, 20-109 days). Compared with 53 patients without clinical deterioration after antituberculosis therapy (control group), patients with paradoxical response were more likely to have extrapulmonary involvement (62.5% vs. 17.0%; P<0.05) at initial diagnosis, to have lower baseline lymphocyte counts (672+/-315 cells/microl vs. 1,328+/-467 cells/microl; P<0.001), and to exhibit a greater surge in lymphocyte counts (627+/-465 cells/microl vs. 225+/-216 cells/microl; P<0.05) during paradoxical response. Further studies on lymphocyte subsets and cytokine levels would be useful in understanding the exact immunological mechanisms involved in immunorestitution.

Publication types

  • Comparative Study

MeSH terms

  • Adult
  • Age Distribution
  • Aged
  • Antitubercular Agents / adverse effects*
  • Antitubercular Agents / therapeutic use
  • Case-Control Studies
  • Chi-Square Distribution
  • Cohort Studies
  • Disease Progression
  • Female
  • Follow-Up Studies
  • HIV Seronegativity
  • Humans
  • Incidence
  • Male
  • Middle Aged
  • Mycobacterium tuberculosis / drug effects
  • Mycobacterium tuberculosis / isolation & purification*
  • Probability
  • Risk Assessment
  • Severity of Illness Index
  • Sex Distribution
  • Treatment Outcome
  • Tuberculin Test
  • Tuberculosis, Pulmonary / diagnosis*
  • Tuberculosis, Pulmonary / drug therapy*

Substances

  • Antitubercular Agents